Filing Flows › Comparisons › BNGO vs PRPO
Bionano Genomics vs Precipio: BNGO and PRPO compared
Bionano Genomics is the larger company: $8.2M of revenue in its latest quarter (Q2 2026) against $7.0M for Precipio (Q2 2026). Precipio is growing faster (+24% against +21% a year earlier). Precipio is more profitable, with an operating margin of -8.5% against -88.3%.
Where the money goes: BNGO and PRPO
Bionano Genomics (BNGO) · Q2 2026
Bionano Genomics, Q2 2026: revenue $8.2M (+21% year over year), operating margin -88.3%, net loss $7.4M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Precipio (PRPO) · Q2 2026
Precipio, Q2 2026: revenue $7.0M (+24% year over year), operating margin -8.5%, net loss $219K, operating cash flow $660K. The chart follows the revenue to costs, profit and cash.
| Bionano Genomics (BNGO) | Precipio (PRPO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $8.2M | $7.0M |
| Revenue growth, Y/Y | +21% | +24% |
| Operating margin | -88.3% | -8.5% |
| Net earnings | −$7.4M | −$219K |
| Net margin | -90.8% | -3.1% |
| Operating cash flow | −$4.7M | $660K |
| Free cash flow | — | $528K |
Where the revenue comes from
Bionano Genomics
- Product: $7.7M (94%)
- Product and Service Other: $478K (6%)
Precipio
- Service revenue, net: $6.1M (87%)
- Product revenue: $906K (13%)
Questions
Which is bigger, Bionano Genomics or Precipio?
Bionano Genomics is the larger company: $8.2M of revenue in its latest quarter (Q2 2026) against $7.0M for Precipio (Q2 2026).
Is Bionano Genomics or Precipio growing faster?
Precipio is growing faster (+24% against +21% a year earlier).
Which is more profitable, Bionano Genomics or Precipio?
Precipio is more profitable, with an operating margin of -8.5% against -88.3%.
More: Bionano Genomics earnings · how Bionano Genomics makes money · Precipio earnings · how Precipio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.